3 Unstoppable Defense Stocks on the Pentagon's Short List

The article highlights a $1.5 trillion initial 2027 U.S. defense budget proposal, up from $1 trillion in 2026, implying $500 billion in incremental spending across defense and space programs. It argues Rocket Lab could benefit from new contracts such as an $816 million missile-detection satellite award, while Lockheed Martin offers steadier, lower-valuation exposure and Palantir has strong revenue growth but trades at a very high 81.5x sales multiple. Overall, the piece is constructive on defense spending but cautious on valuations, especially for Rocket Lab and Palantir.

Analysis

The real tradeable signal here is not “defense spending up,” but the widening split between capital-light software capture and capital-intensive hardware execution. Lockheed looks like the cleaner way to express the budget cycle because it already sits inside procurement processes that favor incumbency, cost-plus visibility, and multi-year sustainment; that tends to monetize budget increases faster than headlines imply. By contrast, Rocket Lab and Palantir are both being valued as if their addressable government revenue is already quasi-certain, which leaves little room for the normal delays in certification, contract ramp, or margin normalization.

Second-order winners are likely to be the suppliers and integrators one layer below the marquee primes, especially firms with cleared manufacturing, propulsion components, or secure data infrastructure. If the Pentagon’s spending impulse is real, the bottleneck is less demand and more throughput: capacity, compliance, and program execution. That favors established primes and picks-and-shovels over “new prime” narratives, because new entrants usually face longer audit cycles and lumpy milestone recognition that can disappoint high-multiple holders even when contracts are awarded.

The contrarian point is that the market may be underestimating how much of this spending is already in the tape for the expensive names and underestimating how sticky defense cash flows are for the cheap name. Palantir’s growth is impressive, but at these levels the burden of proof shifts from “can they win contracts?” to “can they sustain elite growth for years without multiple compression?” In defense, a single quarter of slower bookings or a pause in commercial momentum can hit the stock harder than the underlying business would justify.

Catalyst timing matters: the budget story is a years-long tailwind, but stock performance will likely hinge on 1-3 quarter contract cadence and commentary on backlog conversion. The clearest reversal risk is political or fiscal delay—if appropriations slip or procurement gets phased, high-duration names can de-rate quickly while legacy contractors hold up better. In short, this is a relative-value setup, not a blanket bullish call on the sector.

Key Decisions for Investors

• Overweight LMT on a 6-12 month horizon; use it as the core expression of defense re-rating because it has the best blend of visibility, valuation support, and budget leverage
• Avoid initiating new long PLTR at current levels; if already held, consider trimming into strength and re-enter only on a 15-20% drawdown or after a clear deceleration reset in the multiple
• Keep RKLB on watch only; treat it as a high-beta optionality name and prefer buying via call spreads after contract-to-revenue conversion is visible, not on headline awards alone
• Pair trade: long LMT / short PLTR to express ‘cheap visibility vs expensive perfection’ over the next 3-6 months; this isolates valuation risk while keeping sector exposure neutral
• If looking for thematic upside, use a basket of defense suppliers or subcontractors rather than the highest-profile primes; the near-term beneficiary of budget growth is execution capacity, not narrative